Managing Jaundice Neonatal

Applies the AAP 2022 Clinical Practice Guideline for the Management of Hyperbilirubinemia in the Newborn Infant ≥ 35 Weeks' Gestation. Structures bilirubin risk assessment using the Bhutani hour-specific nomogram, determines phototherapy and exchange transfusion thresholds based on neurotoxicity risk factors, and guides safe discharge planning with follow-up scheduling.

Why This Skill Exists

Neonatal hyperbilirubinemia affects approximately 60% of term and 80% of preterm newborns. While most jaundice is physiologic, failure to identify and treat pathologic hyperbilirubinemia can result in acute bilirubin encephalopathy (ABE) and chronic bilirubin encephalopathy (kernicterus) — an entirely preventable form of brain damage. The AAP 2022 guideline (replacing the 2004 guideline) provides updated, hour-specific phototherapy and exchange transfusion thresholds with explicit neurotoxicity risk factor assessment. This skill enforces the updated protocol.

Checkpoint A — Intake Verification

Required Intake Questions

What is the infant's gestational age (this guideline applies to ≥ 35 weeks)?
What is the infant's age in hours (critical for nomogram plotting)?
What is the maternal and infant blood type and direct Coombs (DAT) result?
What is the current bilirubin level — total serum bilirubin (TSB) or transcutaneous bilirubin (TcB)?
Is the infant breastfeeding? How is feeding going (latch, frequency, urine/stool output)?
What is the infant's current weight and percent weight loss from birth weight?
Are there any neurotoxicity risk factors present (see Step 2)?
Has the infant had a prior bilirubin measurement? If so, what was the rate of rise?

Required Documents

Maternal blood type and antibody screen
Infant blood type and direct antiglobulin test (DAT/Coombs)
Serial bilirubin measurements with time stamps (TSB or TcB)
Birth weight and current weight
Feeding log (type of feeding, frequency, output)
G6PD status (if known or if high-risk ethnicity)

TcB is acceptable for screening but if TcB is within 3 mg/dL of the phototherapy threshold, a confirmatory TSB must be obtained.

Step 1 — Bilirubin Measurement and Risk Zone Assignment (Bhutani Nomogram)

Pre-Discharge Bilirubin Assessment

Obtain TSB or TcB on every newborn before discharge (universal screening per AAP 2022)
Plot the result on the Bhutani hour-specific bilirubin nomogram
Assign risk zone:

| Risk Zone | Percentile Range | Interpretation | |-----------|-----------------|----------------| | Low | < 40th percentile | Low risk for subsequent hyperbilirubinemia | | Low-intermediate | 40th-75th percentile | Needs follow-up; may not need early recheck | | High-intermediate | 75th-95th percentile | Close follow-up required; early recheck | | High | > 95th percentile | At or near phototherapy threshold; may need treatment |

Rate of Rise

Calculate bilirubin rate of rise if ≥ 2 values available
Rate > 0.2 mg/dL/hour in first 24 hours is concerning for hemolysis
Rate > 0.3 mg/dL/hour at any time warrants urgent evaluation

First 24 Hours

Jaundice visible in the first 24 hours of life is ALWAYS pathologic until proven otherwise
Obtain TSB immediately and evaluate for hemolytic disease (blood type incompatibility, G6PD deficiency, spherocytosis)

Step 2 — Neurotoxicity Risk Factor Assessment

The AAP 2022 guideline uses neurotoxicity risk factors to adjust phototherapy and exchange transfusion thresholds. Identify the presence of ANY of the following:

Neurotoxicity Hyperbilirubinemia Risk Factors

Gestational age 35-37 weeks and 6 days (lower GA = higher risk)
Albumin < 3.0 g/dL
Isoimmune hemolytic disease (positive DAT — ABO or Rh incompatibility)
G6PD deficiency
Significant lethargy or sepsis
Acidosis (pH < 7.15)
Instability of clinical condition

Risk Category Assignment

| Category | Definition | Phototherapy Threshold Adjustment | |----------|-----------|----------------------------------| | No risk factors | GA ≥ 38 weeks, no risk factors | Standard thresholds | | With risk factors | Any neurotoxicity risk factor present | Lower thresholds (approximately 2 mg/dL lower) |

Step 3 — Phototherapy Initiation

AAP 2022 Phototherapy Thresholds (Hour-Specific)

Thresholds vary by infant age in hours and risk category. Key representative values for term infants without risk factors:

| Age (hours) | PT Threshold (no risk factors) | PT Threshold (with risk factors) | |-------------|-------------------------------|----------------------------------| | 24 | ~12 mg/dL | ~10 mg/dL | | 48 | ~15 mg/dL | ~13 mg/dL | | 72 | ~18 mg/dL | ~15.5 mg/dL | | 96+ | ~20 mg/dL | ~17.5 mg/dL |

Use the actual AAP 2022 phototherapy nomogram for precise thresholds at each hour of life — the above are approximate reference points.

Phototherapy Technical Standards

Intensive phototherapy delivers ≥ 30 µW/cm²/nm in the 430-490 nm wavelength band
Maximize skin surface area exposure (diaper only, no eye shields blocking forehead)
Proper eye protection (opaque eye shields, check position frequently)
Continue breastfeeding during phototherapy (supplement if intake is inadequate)
Recheck TSB 4-6 hours after initiation; then every 6-12 hours during treatment
Do NOT use sunlight exposure as a substitute for phototherapy

When to Escalate

TSB rising despite phototherapy → verify equipment irradiance, increase skin exposure, consider double or triple lights
TSB approaching exchange transfusion threshold → prepare for potential exchange; notify NICU/transport

Step 4 — Exchange Transfusion Thresholds

Indications for Exchange Transfusion

TSB exceeds exchange transfusion threshold for age in hours and risk category (approximately 5 mg/dL above phototherapy threshold in most cases)
TSB fails to decline by 1-2 mg/dL within 4-6 hours of intensive phototherapy and is approaching exchange threshold
Signs of acute bilirubin encephalopathy (ABE) at ANY bilirubin level

Signs of Acute Bilirubin Encephalopathy (ABE)

Early phase:

Lethargy, hypotonia, poor suck Advanced phase:
Hypertonia (retrocollis, opisthotonos), high-pitched cry, fever
Any neurologic sign attributable to bilirubin → EMERGENT exchange transfusion regardless of TSB level

Exchange Transfusion Protocol

Double-volume exchange (160-180 mL/kg) replaces approximately 85% of circulating RBCs
Reduces TSB by approximately 50%
Requires NICU setting with continuous monitoring
Complications: electrolyte disturbances (hypocalcemia, hyperkalemia), thrombocytopenia, NEC, line complications, cardiac arrhythmia

Step 5 — Discharge Planning and Follow-Up

Pre-Discharge Checklist

Pre-discharge TSB or TcB plotted on Bhutani nomogram with risk zone assigned
Risk factors documented (blood type, DAT, G6PD if applicable, GA)
Feeding assessment: latch, frequency, urine/stool output, percent weight loss

Follow-Up Scheduling Based on Risk Zone and Age at Discharge

| Discharge Age | Risk Zone | Follow-Up | |---------------|-----------|-----------| | < 24 hours | Any | Within 24 hours | | 24-47.9 hours | High or high-intermediate | Within 24 hours | | 24-47.9 hours | Low-intermediate or low | Within 48 hours | | 48-72 hours | High or high-intermediate | Within 24 hours | | 48-72 hours | Low-intermediate or low | Within 48 hours |

Phototherapy Discontinuation

Discontinue when TSB drops 2-3 mg/dL below the phototherapy threshold for age
Recheck TSB 12-24 hours after discontinuation (rebound occurs in ~10-15% of cases)
Higher rebound risk with hemolytic disease and younger gestational age

Breastfeeding Support

Do NOT discontinue breastfeeding for jaundice management
Optimize breastfeeding: 8-12 feeds/day, lactation consultation, supplement with expressed breast milk or formula if intake is insufficient
"Breastfeeding jaundice" (suboptimal intake) is managed by improving breastfeeding, not stopping it
"Breast milk jaundice" (prolonged indirect hyperbilirubinemia after 1 week) rarely requires intervention; TSB > 20 mg/dL warrants evaluation but does not typically require cessation of breastfeeding

Checkpoint B — Jaundice Management Review

[ ] TSB or TcB obtained with exact time stamp and infant age in hours
[ ] Bilirubin plotted on Bhutani nomogram with risk zone documented
[ ] Rate of rise calculated (if ≥ 2 values available)
[ ] Neurotoxicity risk factors systematically assessed and documented
[ ] Phototherapy threshold correctly identified for age and risk category
[ ] If phototherapy initiated: irradiance verified, recheck interval set
[ ] Exchange transfusion threshold identified; team aware if TSB approaching
[ ] ABE signs assessed and documented (lethargy, tone, cry, feeding)
[ ] Breastfeeding status assessed with plan for optimization
[ ] Discharge follow-up scheduled per risk zone
[ ] All [VERIFY] flags resolved or escalated

Quality Audit

| Item | Requirement | Pass? | |------|-------------|-------| | Universal screening | Pre-discharge bilirubin obtained on every newborn | | | Hour-specific plotting | TSB/TcB plotted on Bhutani nomogram at exact age in hours | | | Risk zone assignment | Documented low/low-int/high-int/high | | | Risk factor assessment | All neurotoxicity risk factors systematically evaluated | | | Threshold accuracy | Correct phototherapy threshold applied for age and risk | | | Phototherapy standards | Irradiance ≥ 30 µW/cm²/nm documented | | | Recheck compliance | TSB rechecked 4-6 hours after starting phototherapy | | | ABE screening | Neurologic assessment documented | | | Follow-up scheduling | Post-discharge follow-up within guideline timeframe | | | No unexplained [VERIFY] tags | All flagged items resolved or escalated | |

Guidelines

Follow AAP 2022 Clinical Practice Guideline for Management of Hyperbilirubinemia in Newborns ≥ 35 Weeks' Gestation (replaces 2004 guideline)
Use Bhutani hour-specific bilirubin nomogram for pre-discharge risk stratification
Use AAP 2022 hour-specific phototherapy and exchange transfusion threshold nomograms (separate from Bhutani prediction nomogram)
G6PD deficiency: AAP recommends universal G6PD screening; if not available, screen high-risk populations (African, Mediterranean, Middle Eastern, Southeast Asian descent)
TcB is valid for screening but confirm with TSB when within 3 mg/dL of threshold
Phototherapy irradiance standard: ≥ 30 µW/cm²/nm (intensive) measured at infant skin level
Do not interrupt breastfeeding for jaundice management — optimize feeding support
ABE signs mandate emergent exchange transfusion at any TSB level
Follow AAP safe discharge guidelines: no newborn should be discharged without a bilirubin assessment and follow-up plan
This skill produces clinical documentation; it does not replace clinical judgment